摘要
目的：
1.制备大鼠抗人RANTES分子单克隆抗体(mAb)，并进行初步鉴定，为研究RANTES分子的组织分布和功能提供实验手段。
2.掌握三袖套血管吻合法大鼠节段性异位小肠移植动物模型及静脉营养支持模型的建立方法。
3.将制备的大鼠抗人RANTES单克隆抗体应用于大鼠小肠移植模型,验证其在减轻移植排斥中的作用。
4.对大鼠抗人RNATES单克隆抗体进行初步的人源化改造。
方法：
1.应用杂交瘤技术制备大鼠源性抗人RANTES mAb。ELISA鉴定腹水效价；用Western blot鉴定mAb活性；用流式细胞术、免疫细胞化学技术及免疫组织化学技术对抗体进行鉴定。
2.选用近交系成年雄性SD和Wistar大鼠进行节段性异位小肠移植,采用三袖套血管吻合法。实验分4组，第1组：非手术对照组（SD）；第2组，同基因移植对照组（SD→SD）；第3组：异基因移植未治疗组(SD→Wistar)；第4组，大鼠抗人RANTES mAb治疗组[SD→Wistar +mAb（3mg·kg-1·d-1，ip）]。移植术后3，5，7天分别取各组大鼠移植肠标本（n=6）进行HE染色，观察大体情况及组织病理学变化。
3.应用ELISA试剂盒对术后各组大鼠不同时间点血清IL-2,IL-6,TNF-及RANTES浓度进行检测,并用免疫组化法检测受体大鼠小肠组织内RNATES浓度。
4.利用RT-PCR技术，从杂交瘤细胞株中扩增单克隆抗体VH及VL基因，并连接到人源化表达载体中，经转染293细胞后，纯化表达上清中蛋白分子。
结果：
1.获得2株分泌抗RANTES mAb的杂交瘤细胞株。间接ELISA测定腹水效价均达10-6，一株mAb为IgG1亚类，另一株为IgM；Western blot结果显示两株mAb与人RANTES均有良好的结合活性。在免疫组织化学技术应用中获得较满意效果。
2.异基因移植未治疗组大鼠移植肠组织病理学检查显示移植后第3，5，7天分别出现轻、中、重度排斥反应。同基因移植组和单克隆抗体治疗组均未见明显排斥反应征象。
3.ELISA试剂盒测试结果显示单克隆抗体治疗组与未治疗组相比,大鼠血清中IL-2,IL-6,TNF-及RANTES浓度均明显减低。而小肠组织中RANTES浓度也明显减低。
4.得到2株表达人源化抗体的细胞株,并获得纯化蛋白。结论：
1.制备了两株大鼠抗人RANTES单克隆抗体，这2株单克隆抗体均能应用于Western blot、流式细胞术及免疫细胞化学；而只有No.1抗体株能应用于免疫组织化学技术。
2.将大鼠抗人RANTES单克隆抗体应用于大鼠小肠移植模型，发现其可减轻术后急性排斥反应的发生。
3.改进了大鼠小肠移植模型的制作方法，建立受体大鼠静脉营养支持模型。
4.利用嵌合抗体技术对大鼠抗人RNATES单克隆抗体进行了初步的人源化改造，为进一步表达及应用打下了基础。
AIM
1. To prepare and identify rat monoclonal antibodies against humanRANTES molecule. Provided a new experiment method for research thedistribution and function of RANTES.
2．To master the way of setting up the model of segmental small boweltransplantation heterotopically in rats by tri-cuff anastomosis method, andestablishment of rat model of nutrition support.
3. To apply the rat mAb against human RANTES in rat small boweltransplantation model, validate the effect of mAb in alleviating the transplant rejection.
4. To primary humanize the rat against human RANTES monoclonalantibody.
METHODS
1. Rat mAbs were prepared by hybridoma technique. Ascites titer wasidentified by ELISA. The activities of mAbs were identified by Western bolt.The characters of mAbs were identified by FCM, immunohistochemistry andimmunocytochemistry.
2. Heterotopic small bowel transplant was carried out between inbredmature male SD and Wistar rats, which was used tri-cuff anastomosis method.All recipients were divided into four groups. Group1, SD; Group2, SDSD;Group 3, SDWistar; Group 4, SDWistar+RANTES mAb (3.0mg·kg~(-1)·d~(-1), ip). The grafts were sampled on the postoperative day 3, 5, 7and hematoxylin eosin staining was conducted on the specimens to observepathological change.
3. Checked the concentration of IL-2 , IL-6, TNF- and RANTES in ratserum after operation in four groups at different time by ELISA kit. Checked theconcentration of RANTES in tissue of small bowel of rat receptor byimmunohistochemistry .
4. We got VH and VL gene of mAb from hybridoma cell lines ByRT-PCR,and connected to the humanization expression vectors. Then wepurified the humanized mAb from transfected 293 cell line.
RESULTS
1. Two hybridoma cell lines, RANTES No1, RANTES No2, secreting mAbsagainst human RANTES molecule were obtained. The titers of ascitic mAbsreached to 10-6 and the Ig subclasses of RANTES No1 and RANTES No2 were IgG1 and IgM, respectively. Moreover, RANTES No1 could be used inimmunohistochemistry staining.
2. The pathological examination of grafts in Group 3 demonstrated the mild,moderate, and severe rejection on postoperative day 3, 5, and 7. While rats inthe Group 2 and 4 showed no obvious indication of rejection.
3. The results of ELISA kit detection showed that concentration of IL-2 ,IL-6, TNF- and RANTES in rat serum of mAb therapy group is obviouslydiminution than group 3. Meanwhile, the concentration of RANTES in tissue ofsmall bowel in group 4 is reduced obviously.
4. We got two cell lines which can express humanized monoclonalantibody, and got purified protein by affinity chromatography.
CONCLUSION
1. Prepared two rat mAbs against human RANTES, Both can be used inWestern blot, FCM and immunocytochemistry. Only No.1 can be used inimmunohistochemistry .
2. Applied the rat mAb against human RANTES in rat small boweltransplantation model, validated it can alleviate the transplant rejection.
3. Improved the techniques in rat small bowel transplantation model andestablished the rat model of vein nutrition support.
4. primary humanized the rat against human RANTES monoclonalantibody by chimeric antibody technique, which can provide a useful tool forfurther application.
引文
1. Laing KJ, Secombes CJ. Chemokines[J]. Dev Comp Immunol ,2004 , 28(5) : 443 -460.
2. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation[J]. N Engl J Med, 1998, 338: 436-445.
3. Tournamille C . Molecular basis and structure-activity relationships of the Duffy blood group antigens: chemokine and Plasmodium vivax receptors [J]. Transfus Clin Biol, 2000, 7 (5): 497-509.
4. Richard Horuk. Chemokine receptors [ J ] . Cytokine Growth Factor Rev,2001,12 (4):313-335.
5. Murdoch C , Finn A. Chemokine receptors and their role in inflammation and infectious diseases [J] . Blood, 2000 ,95 (10): 3032-3043.
6. Carvalho-Gaspar M, Billing JS, Spriewald BM, et al. Chemokine gene expression duringallograft rejection: Comparison of two quantitative PCR techniques [J]. J Immunol Methods, 2005,301(1-2): 41-52.
7. Janatpour MJ, Hudak S, SatheM, etal. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment[J]. J Exp Med, 2001, 194: 1375-1384.
8. Solomon MF, Kuziel WA, Simeonovic CJ. The contribution of chemokines and chemokine receptors to the rejection of fetal proislet allografts[J]. Cell Transplant, 2004,13: 503-514.
9.陈实．移植学前沿[M]．武汉：湖北科学技术出版社，2002：111-112．
10. Kapoor A, Fairchild R. Early and late chemokine cascades during acute allograft rejection [J]. Transplant Rev, 2000, 14: 82-95.
11. Belperio JA, Keane MP, Burdick MD,et al. Role of CXCL9 / CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection[J]. J Immunol, 2003,171: 4844-4852.
12. Karason K, Jernas M , Hagg DA,et al. Evaluation of CXCL9 and CXCL10 ascirculating biomarkers of human cardiac allograft rejection[J] . J BMC CardiovascularDisorders , 2006 ,19(6):29.
13.Matz M ,Beyer J , Wunsch D,et al. Early post-transplant urinary IP-10 expression afterkidney transplantation is predictive of short- and long-term graft function [J] . KidneyInt, 2006, 69(9): 1683 -1690.
14.Xanthou G, Duchesnes CE, Williams TJ,et al. CCR3 functional responses are regulatedby both CXCR3 and its ligands CXCL9 , CXCL10 and CXCL11[J] . Eur JImmunol,2003,33: 2241-2250.
15.Panzer U, Reinking RR. Steinmetz OM ,et al. CXCR3 and CCR5 positive T-cellrecruitment in acute human renal allograft rejection[J]. Transplantation, 2004,78:1341-1350.
16. Hancock WW, Gao W, Csizmadia V, et al. Donor-derived IP-10 initiates development of acute allograft rejection[J]. J Exp Med. 2001, 193: 975-980.
17. Hyun JG Lee G, Brown JB, et al. Anti-interferon-inducible chemokine , CXCL10 , reduces colitis by impairing T helper-1 induction and recruitment in mice[J]. Inflamm Bowel Dis , 2005 ,11 : 799-805.
18. Gerard C, Rollins BJ. Chemokines and disease[J]. Nat Immunol, 2001, 2:108-115.
19. Christopherson K, Hromas R. Chemokine regulation of normal and pathologic immune responses[J]. Stem Cells, 2001,19:388-396.
20. Yamada A, Laufer TM, Gerth AJ, et al. Further analysis of the T-cell subsets and pathways of murine cardiac allograft re-rejection[J]. Am J Transplant, 2003, 3: 23-27.
21. Goddard S, W illiams A ,M orland C, et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants [J]. Transplantation, 2001,72:1957-1967.
22.Tanaka T, Bai Z, Srinoulprasert Y,et al. Chemokines in tumor progression and metastasis [J]. Cancer Sci,2005,96(6):317-322.
23. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4[J]. Semin Cancer Biol,2004,4 (3): 171-179.
24. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment[J]. Blood, 2006, 107(5): 1761-1767.
25. Balkwill F .Chemokine biology in cancer[J]. Semin Immunol, 2003 , 15 : 49-55.
26. Zlotnik A. Chemokines and cancer[J]. Int J Cancer, 2006,119(9): 2026.
27. Muller A, Homey B, Soto H,et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature,2001,410 : 50-56.
28. Balkwill F. Cancer and the chemokine network[J]. Nat Rev Cancer, 2004,4: 540-550.
29. Homey B,Zlotnik A,Zlotnik A,et al. Chemokines: agents for the immunotherapy of cancer[J]. Nat Rev Immunol, 2002, 2:175-184.
30. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis [J]. Int J Cancer ,2003, 105: 186-189.
31. Mashino K ,Yamaguchi H ,Yamaguchi H ,et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma[J]. Cancer Res, 2002,62: 2937-2941.
32. Pirtskhalaishvili G. Endothelium-derived factors as paracrine mediators of prostate cancer progression[J]. Prostate, 2000 ,44(1): 77-87.
33. Kawada K ,Sakashita H, Sakashita H,et al. Pivotal role of CXCR3in melanoma cell metastasis to lymph nodes [J]. Cancer Res, 2004, 64(ll):4010-4017.
34. Muller A,Soto H,Soto H,et al. Involvement of chemokine receptors in breast cancer metastasis [J]. Nature, 2001, 410: 50-56.
35. Robledo MM, Longo N ,Longo N,et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells [J]. J Biol Chem, 2001,276(48): 45098-45105.
36. Mori T,Koizumi M,Koizumi M,et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer[J].Mol Cancer Ther,2004,3(l): 29-37.
37. Inoue K, Eve BY .Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer [J]. Clin Cancer Res, 2000,6 (5): 2104-2119.
38. Perissinotto E,Leone F,Leone F,et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression[J] . Clin Cancer Res,2005,l1(2): 490-497.
39. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease[J]. Cancer Cell ,2005,7:211-217.
40. Hedin KE. Chemokines: new, key players in the pathobiology of pancreatic cancer[J]. Int J Gastrointest Cancer, 2002, 31(l):23-29.
41. Ruckes T, Van Snick J ,Van Snick J,et al. Autocrine antiapoptotic stimulation of culturedadult T-cell leukemia cells by overexpression of the chemokine I-309[J].Blood, 2001,98 : 1150- 1159.
42. Salcedo R, Young HA, Young HA,et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression[J].Blood, 2000, 96(l):34-40.
43. Ohta M ,Tanaka S, Tanaka T,et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas[J]. Int J Cancer, 2002 , 102(3):220-224.
44. Varney ML, Mosley R,Mosley T. Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: a paracrine role of tumor-associated macrophages in tumor angiogenesis [J]. In Vivo, 2002,16(6): 471-477.
45. Dias S, Rafii M, Rafii T. The role of CXC chemokines in the regulation of tumor angiogenesis [J]. Cancer Invest, 2001, 19(7):732-738.
46. Addison CL,Morris S,Morris B,et al. The CXC chemokine,monokine induced by interferon- gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis [J]. Hum Gene Ther, 2000, 11(2): 247-261.
47. Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells over-expressing CCL21 generates systemic antitumor responses and confers tumor-immunity[J]. Clin Cancer Res, 2004,10:2891-2901.
48. Sharma S, Stolina M, Luo J, et al. Secondary lymphoid tissue chemokine mediates T cell- dependent antitumor responses in vivo[J]. J Immunol,2000,164: 4558-4563.
49. Scala S,Ascierto PA, Ascierto PA,et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma[J] .Clin Cancer Res,2005, 11: 1835-1841
50. Strieter RM, Burdick MD, Mestas J, et al. Cancer CXC chemokine networks and tumour angiogenesis [J]. Eur J Cancer, 2006, 42: 768-778
51. Zhang F, Lu W, Dong Z. Tumor-infiltrating macrophages are involved In suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice[J]. Clin Cancer Res, 2002,8 (9):2942.
52. Tamamura H,Kanzaki N ,Kanzaki N,et al.T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer[J]. FEBS Lett,2003,550:79-83.
53. Taichman RS, Keller ET,Keller ET,et al. Use of the stromal cellderived factor-1/CXCR4 pathway in prostate cancer metastasis to bone[J]. Cancer Res, 2002 , 62:1832-1837.
54. Princen K, Scholsd. HIV chemokine receptor inhibitors as novel anti-HIV drugs[J]. Cytokine Growth Factor Rev, 2005, 16(6) : 659-677.
55. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor[J]. Science, 1996, 272 (5263) : 872-877.
56. Dean M, Carrington M, Winkler C,et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene [J]. Science, 1996, 273(5283): 1856- 1862.
57. Berger EA, Doms RW, Fenyo EM,et al. A new classification for HIV-1 [J]. Nature, 1998,391 (6664): 240.
58. Choe H,Farzan M,Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates[J]. Cell, 1996, 85(7):1135-1148.
59. Schols D, Proost P, Struyf S,et al. CD26-processed RANTES(3-68) , but not intact RANTES, has potent anti-HIV-1 activity[J]. Antiviral Res, 1998, 39(3):175-187.
60. Lazzeri E,Rom agnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets [J]. Curr Drug Target Immune Endocr Metabol Disord, 2005, 5: 109-118.
61. Golo A, Rainer PW, Jurgen R, et al; CC-chemokine receptor 5( CCR5 ) in hepatitis C -at the crossroads of antiviral immune response [J];Antimicrobial Chemotherapy; 2004,53(6):895 -898.
62. Elise L,Christophe C,Mutsunori I,et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration[J]. Immunology, 2004,173(6):3755 -3762.
63.杨建军，王为忠，李瑞，等．趋化因子受体拮抗剂对大鼠小肠移植的影响[J]第四军医大学学报，2004,25:449-451
64. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, et al. Effect of CCR5-32 and CCR2- 641 alleles on disease progression of perinatally HIV-1 infected children :an international meta-analysis[J].AIDS,2003,17(ll):1631-1638.
65. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity[J].Adv Immunol 2001,78:57-110.
66. Hogaboam CM, Bone Larson C, Matsukawa A, et al. Therapeutic use of the chemokines [J]. Cur Pharma Des, 2000, 6(6):651-663.
67. Nelson PJ, Kim HT, Manning WC, et al. Genomic organization and transcriptional regulation of the RANTES chemokine gene[J]. J.Immunol, 1993, 151: 2061-2067.
68. Donlon TA, Krensky AM, Wallace MR, et al. Localization of a human T-cell-specific gene, RANTES(D17S136E),to chromosome 17qll.2-ql2[J]. Genomics, 1990, 6:548-553.
69. Fairbrother WJ, Skelton NJ. Three-dimensional structures of the chemokine family. In "Chemoattractant Ligands and Their Receptors"(ed.R.Horuk)(M). CRC Press, Boca Raton,FL.
70.Lodi PJ ,Garrett DS, Kuszewski J, et al. High-resolution solution structure of the b chemokine hMIP-1βby multidimensional NMR[J]. Science, 1994,263:1762-1768.
71. Huerta C, Alvarez V, Mata IF, et al. Chemokines (RANTES and MCP-1) and chemokine- receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease[J]. Neurosci Lett, 2004, 370:151-154.
72. Howard OMZ, Benbaruch A, Oppenheim JJ. Chemokines: progress toward identifying molecular targets for therapeutic agents[J]. Trends Biotech,1996,14:46-52.
73. McColl SR, Neote K.Chemotactic factor receptors and signal transduction. In "Chemoattactant Ligands and Their Receptors"(ed.R.Horuk)(M).CRC Press,Boca Raton, FL.1996.
74. Kameyoshi Y, Schoder JM, Christophers E, et al. Identification of the cytokine RANTES released from platelets as an eosinophil chemotactic factor [J]. Int.Arch.Allergy and Immunol, 1994,104:49-56.
75.Ebisawa M, Yamada T, Bickel C, et al. Eosinophil transendothelial migration induced bycytokines.III. Effect of the chemokine RANTES[J]. J.Immunol, 1994,153:2153-2159.
76.Chihara J, Hayashi N, Kakazu T, et al. RANTES augments radical oxygen products fromeosinophils [J]. Int.Arch.Allergy Immunol. 1994, 104:52-57.
77.Baggiollini M, Dahinden CA. C-C chemokines in allergic inflammation. Immunol.Today, 1994, 15:27-31.
78.Alkhatib Q Combadiere C, Broder CC, et al. CCCKR5: ARANTES, MIP-la,MIP-1β receptor asa fusion cofactor for macrophage-tropicHIV-l[J].Science,1996,272:1955-1963.
79. Pattison J, Nelson PJ, Huie P, et al. RANTES chemokine expression in cell-mediatedtransplant rejection of the kidney[J]. Lancet, 1994, 343:209-211.
80. Fairchild RL, VanBuskirk AM, Kondo T,et al. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts[J]. Transplantation, 1997,63(12): 1807-1812.
81. Mulligan H, McDuffie JE, Shanley TP, et al. Role of RANTES in experimental cardiac allograft rejection[J]. Exp Mol Pathol, 2000,69: 167-174
82. Monti G ,Fattal M ,Fattal M, et al. Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation Transplantation[J].1996,61(12):1757-1762.
83. Kimmel PL, Bodi I, Abraham A, et al. Increased renal tissue cytokines in human HIV nephropathy[J].J.Am.Soci.Nephrol,1993,4:279-283.
84. Snowden N, Hajeer A, Thomson W, et al. RANTES role in rheumatoid arthritis. Lancet, 1994,343:547-552.
85. Struyf S, De Meester I, Scharpe S ,et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3 ,impairs its chemotactic potency and generates a CC chemokine inhibitor[J]. Eur J Immunol, 1998 ,28(4) :1262-1271.
86. Bonville CA, Lau VK, De Leon JM, et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo[J]. J Virol, 2004,78 (15): 7984-7989.
87. Okumura M, Mester M. The coming of age of small bowel transplantation: a historical perspective [J]. Transplant Proc. 1992, 24 (3): 1241-1242.
88.李宁，黎介寿，小肠移植.见：夏穗生主编.临床移植医学(M).杭州：浙江科技出版社， 1999;438-450.
89.王为忠，宋维亮.活体部分小肠移植一例报告[J].中华器官移植杂志，2001;22(1):30-32
90. Langnas AN. Advances in small-intestine transplantation[J]. Transplantation, 2004, 77:575-578.
91. Sudan DL, Kaufman SS, Shaw BW, et al. Isolated intestinal transplantation for intestinal failurefJ]. Am J Gastroenterol, 2000,95(6): 1506-1515.
92.Ghanekar A, Grant G. Small bowel transplantation[J]. Curr Opin CritCare,2001,7(2): 133-137.
93.Kumar N, Grant D. Gastrointestinal transplantation: an update [J] .Liver Transpl, 2000, 6(4) :515-519.
94. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody ofpredefined specificity[J]. Nature, 1975, 256:495-497.
95.Riechmann L,Clark M, Waldmann H, et al. Reshaping human antibodies for therapy[J].Nature, 1988,332:323-327.
96.罗萍.治疗性单克隆抗体研究进展及临床应用现状[J].第三军医大学报, 2004 , 26(5) : 454-456.
97. Vanhoefer U , Tewes M, Rojo F ,et al . Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epiderma Growth Factor Receptor[J]. J Clin Oncol ,2004 ,22 (1) :175-184.
98.沈倍奋，陈志南，刘民培.主编.重组抗体(M).北京:科学出版社,2005,288.
99.Pedersen JT, Henry A H, Searle SMJ, et al. Comparison of surface accessible residues inhuman and murine immunoglobulin FV domains: Implication for humanization ofmurine antibodies [J]. J Mol Biol,1994,235(3):959.
100. http :/ / www. pharmtec. org. cn/ allpage/ newsAll/ contentl. lOl.Rader C, Cheresh DA, Barbas CF.Phage display approach for rapidantibodyhumanization: Designed combinatorial V gene libraries [J]. Proc Natl Acid SciUSA,1998,95(15):8910- 8915.
102. Jespers L S, Roberts A, Mahler SM, et al. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen[J].Bio Techology,1994,12(9):899- 903.
103. Verma R ,Boleti E ,George AJ . Antibody engineering : comparison of bacterial , yeast ,insect and mammalian expression systems [J]. J Immunol Methods , 1998 , 216(122):165-181.
104.林芸,阎锡蕴.人源化抗体研究进程及发展趋势[J].生物工程学报, 2004 ,20(1) :1-5.
105.Tam SH , Sassoli PM, Jordan RE , et al . AbcixiMAb ( ReoPro , chimeric 7E3 Fab)demonstrates equivalent affinity and functional blockade of glycoprotein IIb/ IIIa andalpha (v) beta3 integrins[J]. Circulation ,1998 ,98(11) :1085-1091.
106.Danoff TM, Lalley PA, Chang YS, et al. Cloning, genomic organization,andchromosomal localization of the Scya5 gene encoding the murine chemokineRANTES[J]J.Immunol.l994, 152:1182-1187.
107.Fujita H, Asahina A, Gao P, et al. Expression and regulation of RANTES/ CCL5,MIP-1 alpha/ CCL3, and MIP-lbeta/CCL4 in mouse Langerhans cells[J]. J InvestDermatol. 2004,122:1331 -1333.
108.彭曦,汪仕良,谭银铃,等.大鼠静脉输液装的设计和制作[J] .第三军医大学报,1999,21(7):532-533
109.Toogood GJ, Rankin AM, Tarn PKH. The immune response following small boweltransplantation II : Very early cyroline expression in the gut-associated lymphoidtissue[J]. Transplantation, 1997;63:1118-1123.
110.Sonoda KH, Sasa Y, Qiao H, et al. Immunoregulatory role of ocular macrophages: themacrophages produce RANTES to suppress experimental autoimmune uveitis[J]. JImmunol. 2003 ,171:2652-2659.
111. Xia M, Leppart D, Hauser SL, et al. Stimulus-specificity of matrix metalloproteinase-dependence of human T cell migration through a model basement membrane[J]. J.Immunol. 1996,156:160-168.
112. Newell KA. Transplantation of the intestine: is it truly different[J] ? Am J Transplant, 2003, 3(l):l-2.